Meeting
2020 ASCO Virtual Scientific Program
A proteomic biomarker discovery platform for predicting clinical benefit of immunotherapy in advanced melanoma.
Authors
Yuval Shaked
Technion, Haifa, Israel
Yuval Shaked , Michal Harel , Eran Issler , Ella Fremder , Eyal Jacob , Nili Dahan , Haim Bar , Ruth Halaban , Mario Sznol , Ofer Sharon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10037)
DOI
10.1200/JCO.2020.38.15_suppl.10037
Abstract #
10037
Poster Bd #
386
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Effect of immunotherapy and time-of-day infusion chronomodulation on survival in advanced cancers.
First Author: Blessie Elizabeth Nelson
Poster
2019 ASCO Annual Meeting
c-AMP/MAPK dysregulation and its impact on survival and response to immunotherapy in advanced melanomas.
First Author: Rami Al-Rohil
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy.
First Author: Tuba Nur Gide
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC).
First Author: T.R. Jeffry Evans